期刊
EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY
卷 12, 期 12, 页码 1183-1191出版社
TAYLOR & FRANCIS LTD
DOI: 10.1080/17474124.2018.1545574
关键词
Inflammatory bowel disease; Crohn's disease; ulcerative colitis; azathioprine; mercaptopurine; methotrexate; anti-TNF; anti-integrin; anti-IL 12/IL 23
Introduction: Crohn's disease and ulcerative colitis affect an increasing number of patients, and utilization of immune suppressant and biologic therapies is also increasing. These agents are linked to adverse events ranging from mild nuisance symptoms to potentially life-threatening complications including infections and malignancies. Areas covered: This review provides an updated discussion on adverse events associated with immunomodulator, anti-TNF-a, anti-integrin, and anti-IL 12/IL-23 antibody therapies. In addition, we review the risk profile of the currently widely available infliximab biosimilar medication. Expert commentary: Providers should engage in risk-benefit discussion with information specific to each medication discussed, and consider individualized risk factors when selecting therapeutic agents. Drug monitoring and shared decision-making results in more personalized medical management of inflammatory bowel disease.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据